Cooper Financial Group acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,882 shares of the specialty pharmaceutical company’s stock, valued at approximately $300,000.
Other hedge funds have also modified their holdings of the company. Prudential Financial Inc. increased its position in Jazz Pharmaceuticals by 3,731.5% during the third quarter. Prudential Financial Inc. now owns 311,383 shares of the specialty pharmaceutical company’s stock worth $41,503,000 after buying an additional 303,256 shares in the last quarter. Samlyn Capital LLC raised its stake in Jazz Pharmaceuticals by 28.1% in the 2nd quarter. Samlyn Capital LLC now owns 1,203,559 shares of the specialty pharmaceutical company’s stock valued at $187,767,000 after purchasing an additional 264,146 shares during the last quarter. Woodline Partners LP lifted its holdings in Jazz Pharmaceuticals by 126.7% in the 2nd quarter. Woodline Partners LP now owns 396,861 shares of the specialty pharmaceutical company’s stock valued at $61,914,000 after purchasing an additional 221,818 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Jazz Pharmaceuticals by 7.5% during the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock worth $408,654,000 after purchasing an additional 184,124 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Jazz Pharmaceuticals by 18.3% during the second quarter. Franklin Resources Inc. now owns 1,181,772 shares of the specialty pharmaceutical company’s stock worth $184,368,000 after buying an additional 182,588 shares in the last quarter. 89.79% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several brokerages recently issued reports on JAZZ. HC Wainwright reissued a “buy” rating and set a $204.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, March 6th. StockNews.com initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, March 16th. They set a “buy” rating on the stock. The Goldman Sachs Group lifted their price objective on Jazz Pharmaceuticals from $190.00 to $212.00 and gave the company a “buy” rating in a research report on Friday, March 3rd. Finally, Needham & Company LLC reduced their target price on Jazz Pharmaceuticals from $210.00 to $205.00 and set a “buy” rating on the stock in a research report on Thursday, March 2nd. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $204.27.
Jazz Pharmaceuticals Stock Down 0.9 %
Insider Activity at Jazz Pharmaceuticals
In related news, CEO Bruce C. Cozadd sold 3,000 shares of the stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $159.86, for a total value of $479,580.00. Following the completion of the sale, the chief executive officer now directly owns 368,078 shares in the company, valued at approximately $58,840,949.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, SVP Samantha Pearce sold 531 shares of the business’s stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $159.59, for a total transaction of $84,742.29. Following the transaction, the senior vice president now directly owns 11,309 shares of the company’s stock, valued at approximately $1,804,803.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 3,000 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $159.86, for a total transaction of $479,580.00. Following the completion of the sale, the chief executive officer now directly owns 368,078 shares of the company’s stock, valued at approximately $58,840,949.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,111 shares of company stock worth $2,056,822. 4.40% of the stock is currently owned by corporate insiders.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.
Further Reading
- Get a free copy of the StockNews.com research report on Jazz Pharmaceuticals (JAZZ)
- What is the Consumer Staples Sector?
- What is a Consumer Staples Index Fund?
- Bitcoin Might Better Than Bitcoin Stocks and ETFs,
- GameStop Shares Surge On Surprise Profit
- Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
